Small Molecule Reprogramming Digestive Epithelial Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reprogramming cells into endodermal stem/progenitor cells face challenges such as epigenetic barriers and the need for transcription factors, which can lead to safety concerns and limited efficiency, especially when transitioning from mesoderm-derived cells like fibroblasts to endoderm-derived cells like those found in the digestive tract.
Innovation Solution
A small molecule compound combination, including SB431542, VPA, PD0325901, RG108, Bix01294, Bay K 8644, PS48, and FBP, or their variants, is used to reprogram digestive tract-derived epithelial cells into endodermal stem/progenitor cells, supported by gastric or intestinal subepithelial myofibroblasts as feeder cells, avoiding the need for transcription factor overexpression and enhancing reprogramming efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transcription factors are used for reprogramming, then reprogramming capability is achieved, but safety concerns arise due to potential genomic integration and tumorigenicity
Solution Approach 1:
The patent replaces the mechanical/genetic system of transcription factor delivery (viral vectors, plasmids) with a chemical system using small molecule compounds. This substitution eliminates the risk of genomic integration and tumorigenicity associated with genetic methods while achieving the same reprogramming outcome through epigenetic modulation and signaling pathway regulation.
Solution Approach 2:
The patent changes the fundamental parameter of reprogramming from genetic modification to chemical modulation. By using small molecules that temporarily modulate cellular signaling pathways and epigenetic states, the method achieves reprogramming without permanent genetic changes, thereby improving safety while maintaining reprogramming capability.
2Ease of manufacture
If fibroblasts are used as starting cells, then ease of acquisition is improved, but epigenetic barriers prevent efficient reprogramming to endodermal cells
Solution Approach 1:
The patent introduces an intermediary approach by using a sequential reprogramming strategy that first induces a pluripotent intermediate state, then transitions to the target endodermal state. This two-stage process uses specific small molecule combinations to bridge the epigenetic gap between fibroblasts and endodermal cells, overcoming the direct reprogramming barrier while maintaining ease of cell acquisition.
3Reliability
If small molecule compounds are used for reprogramming, then safety is improved by avoiding transcription factors, but reprogramming efficiency was previously limited
Solution Approach 1:
The patent employs a composite approach by combining multiple small molecule compounds into specific formulations that work synergistically. Each compound targets different aspects of the reprogramming process (epigenetic modification, signaling pathway regulation, metabolic reprogramming), and their combination achieves high efficiency that individual compounds cannot accomplish alone, while maintaining the safety advantages of non-genetic methods.
Data Source
Figure 1~3
Figure 4
Figure 5~7
AI summary
Provided are a small molecule compound combination for reprogramming digestive tract derived epithelial cells to endodermal stem/progenitor cells, a reprogramming method and an application. Human gastric epithelial cells (hGECs) are used as initiating cells, human gastric subepithelial myofibroblasts (aGSEMFs) are used as a trophoblast, a compound combination having all or a plurality of FBP, Bay K 8644, Bix01294, SB431542 or A83-01, VPA, RG108, PD0325901 and PS48 including SB or A83 is used to reprogram digestive tract derived epithelial cells to endodermal stem/progenitor cells, and the endodermal stem/progenitor cells can be used for inducing differentiation towards liver cells, pancreatic beta cells and intestinal cells.